- Avicanna (TSX:AVCN) has revealed it has completed the retrospective observational real-world evidence study of its RHO Phyto branded Ultra CBD topical cream on patients with epidermolysis bullosa
- Epidermolysis bullosa is a rare condition that causes blistering and fragile skin
- The study took place at The Hospital for Sick Children in Toronto and evaluated the tolerability and efficacy of RHO Phyto-branded Ultra CBD Topical Cream in patients with the condition
- Shares of Avicanna are up 1.56 per cent to C$0.32 as of 11:47 am ET
Avicanna (TSX:AVCN) has revealed it has completed the retrospective observational real-world evidence study of its RHO Phyto branded Ultra CBD topical cream on patients with epidermolysis bullosa.
Epidermolysis bullosa is a rare condition that causes blistering and fragile skin.
In a news release, the company stated the study took place at The Hospital for Sick Children in Toronto and evaluated the tolerability and efficacy of RHO Phyto-branded Ultra CBD Topical Cream in patients with the condition.
The RHO Phyto-branded Ultra CBD Topical Cream is an oil-based 3 per cent CBD localized cream developed to target dermatology conditions.
In total, 20 patients – 14 male patients and six female patients – were enrolled with an average age of 17.3 years with various subtypes of epidermolysis bullosa.
Roughly 55 per cent of the enrolled patients showed improvement in wound healing while 45 per cent displayed wound stability over six months.
“We are pleased to see the study reporting early positive results for RHO Phyto-branded Ultra CBD Topical Cream in a patient population that continues to seek treatment for its catastrophic condition,” Karolina Urban, Ph.D. and executive vice president of medical affairs at Avicanna, said in a statement. “These results are critical in helping guide us in the next steps in the further development of our medical products and pharmaceutical pipeline.”
Epidermolysis bullosa is a rare group of inherited diseases that cause fragile skin, leading to blistering and tearing. There is no cure or accepted disease-modifying treatments of the condition. As it currently stands, treatment is palliative to promote patient well-being.
Avicanna is a commercial-stage international biopharmaceutical company focused on advancing cannabinoid-based products and formulations for the global medical and pharmaceutical market segments.
Shares of Avicanna (TSX:AVCN) are up 1.56 per cent to C$0.32 as of 11:47 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Avicanna Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.